GRAIL, Inc. (GRAL)
59.71
+1.12
(+1.91%)
USD |
NASDAQ |
Jun 11, 10:56
GRAIL Enterprise Value : 1.638B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 1.638B |
| June 09, 2026 | 1.733B |
| June 08, 2026 | 1.759B |
| June 05, 2026 | 1.695B |
| June 04, 2026 | 1.965B |
| June 03, 2026 | 1.742B |
| June 02, 2026 | 1.692B |
| June 01, 2026 | 1.877B |
| May 29, 2026 | 2.176B |
| May 28, 2026 | 2.269B |
| May 27, 2026 | 2.293B |
| May 26, 2026 | 2.187B |
| May 22, 2026 | 2.111B |
| May 21, 2026 | 2.140B |
| May 20, 2026 | 2.062B |
| May 19, 2026 | 1.845B |
| May 18, 2026 | 1.833B |
| May 15, 2026 | 1.788B |
| May 14, 2026 | 1.880B |
| May 13, 2026 | 1.823B |
| May 12, 2026 | 1.888B |
| May 11, 2026 | 1.857B |
| May 08, 2026 | 1.873B |
| May 07, 2026 | 1.928B |
| May 06, 2026 | 1.921B |
| Date | Value |
|---|---|
| May 05, 2026 | 1.563B |
| May 04, 2026 | 1.617B |
| May 01, 2026 | 1.548B |
| April 30, 2026 | 1.566B |
| April 29, 2026 | 1.360B |
| April 28, 2026 | 1.468B |
| April 27, 2026 | 1.589B |
| April 24, 2026 | 1.563B |
| April 23, 2026 | 1.402B |
| April 22, 2026 | 1.485B |
| April 21, 2026 | 1.328B |
| April 20, 2026 | 1.334B |
| April 17, 2026 | 1.355B |
| April 16, 2026 | 1.263B |
| April 15, 2026 | 1.276B |
| April 14, 2026 | 1.305B |
| April 13, 2026 | 1.204B |
| April 10, 2026 | 1.105B |
| April 09, 2026 | 1.184B |
| April 08, 2026 | 1.317B |
| April 07, 2026 | 1.250B |
| April 06, 2026 | 1.356B |
| April 02, 2026 | 1.490B |
| April 01, 2026 | 1.433B |
| March 31, 2026 | 1.354B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Apogee Therapeutics, Inc. | 5.142B |
| Evommune, Inc. | 535.67M |
| Arrowhead Pharmaceuticals, Inc. | 9.517B |
| Oncolytics Biotech, Inc. | 87.93M |
| Sangamo Therapeutics, Inc. | 53.47M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -93.19M |
| Revenue (Quarterly) | 40.78M |
| Total Expenses (Quarterly) | 133.97M |
| EPS Diluted (Quarterly) | -2.293 |
| Gross Profit Margin (Quarterly) | -37.81% |
| Profit Margin (Quarterly) | -228.5% |
| Earnings Yield | -17.38% |
| Normalized Earnings Yield | -16.46 |